Literature DB >> 1610320

Hepatic cavernous haemangioma: a 10 year review.

N Tait1, A J Richardson, G Muguti, J M Little.   

Abstract

Between January 1981 and July 1991, 61 patients with hepatic haemangiomata were examined at Westmead Hospital. There were 14 males (22%) and 47 females (78%). The age range was 26-85 years with a median of 49 years. Forty-one had abdominal symptoms but these could be attributed to a haemangioma in only seven cases. There was at least one subcapsular lesion in 17 (28%). Six of the seven symptomatic lesions were subcapsular and five of these were giant haemangiomata (i.e. more than 4 cm in greatest diameter). One large symptomatic lesion was intrahepatic. No association was observed between hepatic haemangiomata and other hepatic or extrahepatic diseases. Haemangiomata were resected from six patients, four of whom were symptomatic. Symptoms improved in all four but did not resolve completely in any. Follow-up ranged from nil in five patients to 108 months in one. The median follow-up was 12 months after initial diagnosis. Ten patients showed evidence of change in their lesions or symptoms while under observation. Only three had worsening symptoms or suspected change in size of a haemangioma. This study highlights the benign, static nature of most hepatic haemangiomata. When this lesion is suspected, the diagnosis should be confirmed with ultrasound (US) and labelled red blood cell scanning (RBCS). Referral for evaluation by a specialist hepatobiliary surgery unit is necessary when symptoms are intolerable, increasing size is definitely demonstrated or the diagnosis is uncertain and cannot be established without specialized investigations. Bleeding into or from these lesions is rare.

Entities:  

Keywords:  Age Distribution; Age Factors; Australia; Biology; Contraception; Contraceptive Methods--side effects; Demographic Factors; Developed Countries; Diseases; Examinations And Diagnoses; Family Planning; Hepatic Effects; Histology; Oceania; Oral Contraceptives--side effects; Physiology; Population; Population Characteristics; Research Methodology; Retrospective Studies; Sex Distribution; Sex Factors; Signs And Symptoms; Studies; Treatment

Mesh:

Substances:

Year:  1992        PMID: 1610320     DOI: 10.1111/j.1445-2197.1992.tb07043.x

Source DB:  PubMed          Journal:  Aust N Z J Surg        ISSN: 0004-8682


  3 in total

Review 1.  Postoperative severe microangiopathic hemolytic anemia associated with a giant hepatic cavernous hemangioma.

Authors:  Kaysie L Banton; Jonathan D'Cunha; Noel Laudi; Catherine Flynn; Dale Hammerschmidt; Abhinav Humar; Timothy Sielaff
Journal:  J Gastrointest Surg       Date:  2005 May-Jun       Impact factor: 3.452

2.  Hepatic sclerosed hemangioma with special attention to diffusion-weighted magnetic resonance imaging.

Authors:  Tatsunori Miyata; Toru Beppu; Kunitaka Kuramoto; Shigeki Nakagawa; Katsunori Imai; Daisuke Hashimoto; Tomohiro Namimoto; Yo-Ichi Yamashita; Akira Chikamoto; Yasuyuki Yamashita; Hideo Baba
Journal:  Surg Case Rep       Date:  2018-01-03

3.  KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K-MAPK1 inhibition.

Authors:  Harish Palleti Janardhan; Xiuling Meng; Karen Dresser; Lloyd Hutchinson; Chinmay M Trivedi
Journal:  J Exp Med       Date:  2020-07-06       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.